Drug intelligence / Profile preview

RQ3025

Development stage: Phase 1
Lead developer: Shanghai Lanque Biomedical
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Injection

Overview

RQ3025 is an investigational **bivalent lipid-nanoparticle-formulated modified mRNA COVID-19 vaccine** developed to broaden immunity against SARS-CoV-2 variants. It contains two mRNA components, RQ3013 and RQ3019, encoding chimeric near-full-length SARS-CoV-2 spike antigens representing Alpha/Beta and Omicron BA.2/BA.4/BA.5-associated mutations, respectively. Following intramuscular administration, host cells translate the mRNAs and present spike antigens, inducing variant-reactive neutralizing antibodies and cellular immune responses. RQ3025 has been evaluated as a booster in COVID-19 vaccine-experienced adults and generated broader neutralizing-antibody responses than the predecessor monovalent RQ3013 vaccine in reported studies.

Other names: RQ-3025RQ3025RQ 3025

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on RQ3025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ3025.

Explore the full profile